You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBethanidine
Accession NumberDB00217  (APRD00825)
TypeSmall Molecule
GroupsApproved
DescriptionA guanidinium antihypertensive agent that acts by blocking adrenergic transmission.
Structure
Thumb
Synonyms
Betanidina
Betanidine
Betanidinum
N,N'-dimethyl-N''-(phenylmethyl)-guanidine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EsbatalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bethanidine sulfate
114-85-2
Thumb
  • InChI Key: YTIJUXVIZLYQTB-UHFFFAOYSA-N
  • Monoisotopic Mass: 452.220574232
  • Average Mass: 452.571
DBSALT000194
Categories
UNIIW8S3YM7AUU
CAS number55-73-2
WeightAverage: 177.2462
Monoisotopic: 177.126597495
Chemical FormulaC10H15N3
InChI KeyNIVZHWNOUVJHKV-UHFFFAOYSA-N
InChI
InChI=1S/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)
IUPAC Name
(E)-3-benzyl-1,2-dimethylguanidine
SMILES
CN\C(NCC1=CC=CC=C1)=N/C
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications Not Available
PharmacodynamicsBethanidine is a guanidinium antihypertensive agent that acts by blocking adrenergic transmission. The precise mode of action is not clear. Although bethanidine may produce adverse effects, they are beneficial in severe hypertension and produce fewer side effects than guanethidine.
Mechanism of actionBethanidine, a guanidine derivative, is a peripherally acting antiadrenergic agent which primarily acts as an alpha2a adrenergic agonist. Bethanidine effectively decreases blood pressure by suppressing renin secretion or interfering with function of the sympathetic nervous system.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2 adrenergic receptorProtein groupyes
agonist
Humannot applicabledetails
ATP-sensitive inward rectifier potassium channel 1Proteinyes
inhibitor
HumanP48048 details
Beta adrenergic receptorProtein groupunknown
antagonist
Humannot applicabledetails
Related Articles
AbsorptionAbsorbed rapidly in the gastrointestinal tract following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life9 hours (range 7 to 11 hours)
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bethanidine.Experimental
AcebutololBethanidine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Bethanidine.Approved, Investigational
AliskirenBethanidine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololBethanidine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanBethanidine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineBethanidine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Bethanidine.Illicit, Withdrawn
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Bethanidine.Approved
AmlodipineBethanidine may increase the hypotensive activities of Amlodipine.Approved
Aop200704Bethanidine may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ArotinololBethanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
AtenololBethanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
BefunololBethanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBethanidine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideBethanidine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bethanidine.Withdrawn
BepridilBethanidine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBethanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BimatoprostBethanidine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBethanidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololBethanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BosentanBethanidine may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumBethanidine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBethanidine may increase the hypotensive activities of Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Bethanidine.Approved
BucindololBethanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBethanidine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololBethanidine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
CandesartanBethanidine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilBethanidine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilBethanidine may increase the hypotensive activities of Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Bethanidine.Withdrawn
CarteololBethanidine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBethanidine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololBethanidine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
ChlorothiazideBethanidine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneBethanidine may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilBethanidine may increase the hypotensive activities of Cilazapril.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Bethanidine.Approved, Vet Approved
ClonidineBethanidine may increase the hypotensive activities of Clonidine.Approved
CryptenamineBethanidine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Bethanidine.Approved
CyclothiazideBethanidine may increase the hypotensive activities of Cyclothiazide.Approved
DebrisoquinBethanidine may increase the hypotensive activities of Debrisoquin.Approved
DeserpidineBethanidine may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Bethanidine.Approved
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Bethanidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bethanidine.Approved
DihydralazineBethanidine may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemBethanidine may increase the hypotensive activities of Diltiazem.Approved
DorzolamideBethanidine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Bethanidine.Approved
DoxazosinBethanidine may increase the hypotensive activities of Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Bethanidine.Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Bethanidine.Approved
EfonidipineBethanidine may increase the hypotensive activities of Efonidipine.Approved
EnalaprilBethanidine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBethanidine may increase the hypotensive activities of Enalaprilat.Approved
EpoprostenolBethanidine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBethanidine may increase the hypotensive activities of Eprosartan.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Bethanidine.Investigational
EsmololBethanidine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
FelodipineBethanidine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamBethanidine may increase the hypotensive activities of Fenoldopam.Approved
FosinoprilBethanidine may increase the hypotensive activities of Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Bethanidine.Approved, Vet Approved
GuanabenzBethanidine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelBethanidine may increase the hypotensive activities of Guanadrel.Approved
GuanethidineBethanidine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineBethanidine may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumBethanidine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of Bethanidine.Approved
HydralazineBethanidine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBethanidine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBethanidine may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Bethanidine.Approved, Investigational
ImidaprilBethanidine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Bethanidine.Approved
IndapamideBethanidine may increase the hypotensive activities of Indapamide.Approved
IndenololBethanidine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminBethanidine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Bethanidine.Approved
IproclozideIproclozide may increase the hypotensive activities of Bethanidine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Bethanidine.Withdrawn
IrbesartanBethanidine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bethanidine.Approved
IsradipineBethanidine may increase the hypotensive activities of Isradipine.Approved
KetanserinBethanidine may increase the hypotensive activities of Ketanserin.Investigational
LabetalolBethanidine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineBethanidine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostBethanidine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineBethanidine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Bethanidine.Approved
LisinoprilBethanidine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineBethanidine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanBethanidine may increase the hypotensive activities of Losartan.Approved
MacitentanBethanidine may increase the hypotensive activities of Macitentan.Approved
ManidipineBethanidine may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Bethanidine.Withdrawn
MecamylamineBethanidine may increase the hypotensive activities of Mecamylamine.Approved
MethyldopaBethanidine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bethanidine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bethanidine.Approved, Investigational
MetipranololBethanidine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneBethanidine may increase the hypotensive activities of Metolazone.Approved
MetoprololBethanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineBethanidine may increase the hypotensive activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Mianserin.Approved
MibefradilBethanidine may increase the hypotensive activities of Mibefradil.Withdrawn
MilnacipranMilnacipran may decrease the antihypertensive activities of Bethanidine.Approved
MinaprineMinaprine may increase the hypotensive activities of Bethanidine.Approved
MinoxidilBethanidine may increase the hypotensive activities of Minoxidil.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Bethanidine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Bethanidine.Approved
MoexiprilBethanidine may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Bethanidine.Approved
MoxonidineBethanidine may increase the hypotensive activities of Moxonidine.Approved
NadololBethanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilBethanidine may increase the hypotensive activities of Naftopidil.Investigational
NebivololBethanidine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Bethanidine.Withdrawn
NicardipineBethanidine may increase the hypotensive activities of Nicardipine.Approved
NicorandilBethanidine may increase the hypotensive activities of Nicorandil.Approved
NiguldipineBethanidine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBethanidine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineBethanidine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineBethanidine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineBethanidine may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideBethanidine may increase the hypotensive activities of Nitroprusside.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Bethanidine.Approved
ObinutuzumabBethanidine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Bethanidine.Withdrawn
OlmesartanBethanidine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OmapatrilatBethanidine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolOpipramol may decrease the antihypertensive activities of Bethanidine.Investigational
OxprenololBethanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Bethanidine.Approved
PenbutololBethanidine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentoliniumBethanidine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bethanidine.Approved, Investigational
PerindoprilBethanidine may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Bethanidine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bethanidine.Withdrawn
PhenoxybenzamineBethanidine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bethanidine.Withdrawn
PhentolamineBethanidine may increase the hypotensive activities of Phentolamine.Approved
PinacidilBethanidine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololBethanidine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Bethanidine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Bethanidine.Withdrawn
PolythiazideBethanidine may increase the hypotensive activities of Polythiazide.Approved
PractololBethanidine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinBethanidine may increase the hypotensive activities of Prazosin.Approved
PropranololBethanidine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Bethanidine.Approved
QuinaprilBethanidine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Bethanidine.Approved
RamiprilRamipril may increase the hypotensive activities of Bethanidine.Approved
RasagilineRasagiline may increase the hypotensive activities of Bethanidine.Approved
RemikirenRemikiren may increase the hypotensive activities of Bethanidine.Approved
RescinnamineBethanidine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Bethanidine.Approved
RilmenidineBethanidine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatBethanidine may increase the hypotensive activities of Riociguat.Approved
RituximabBethanidine may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Bethanidine.Withdrawn
SaprisartanBethanidine may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Bethanidine.Approved, Investigational, Vet Approved
SelexipagBethanidine may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Bethanidine.Approved, Investigational
SitaxentanBethanidine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolBethanidine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilBethanidine may increase the hypotensive activities of Spirapril.Approved
TadalafilTadalafil may increase the antihypertensive activities of Bethanidine.Approved, Investigational
TelmisartanBethanidine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilBethanidine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerlipressinBethanidine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TianeptineTianeptine may decrease the antihypertensive activities of Bethanidine.Approved
TiboloneBethanidine may increase the hypotensive activities of Tibolone.Approved
TicrynafenBethanidine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololBethanidine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TolazolineBethanidine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Bethanidine.Approved
TorasemideTorasemide may increase the hypotensive activities of Bethanidine.Approved
TrandolaprilBethanidine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bethanidine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Bethanidine.Approved
TravoprostBethanidine may increase the hypotensive activities of Travoprost.Approved
TreprostinilBethanidine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideBethanidine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBethanidine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBethanidine may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Bethanidine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Bethanidine.Approved, Investigational
UnoprostoneBethanidine may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Bethanidine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Bethanidine.Approved
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Bethanidine.Approved
VinpocetineBethanidine may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineBethanidine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Bethanidine.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis Reference

Khashayar Karimian, Keshava Murthy, Darren Hall, “Methods of making ureas and guanidines, including terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin, and bunazosin (exemplary of 2-substituted quinazoline compounds), and meobentine, and bethanidine and intermediates thereof.” U.S. Patent US5686612, issued November, 1990.

US5686612
General ReferencesNot Available
External Links
ATC CodesC02CC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9713
Blood Brain Barrier+0.85
Caco-2 permeable+0.5072
P-glycoprotein substrateNon-substrate0.5681
P-glycoprotein inhibitor INon-inhibitor0.9217
P-glycoprotein inhibitor IINon-inhibitor0.6727
Renal organic cation transporterInhibitor0.5516
CYP450 2C9 substrateNon-substrate0.7952
CYP450 2D6 substrateNon-substrate0.5
CYP450 3A4 substrateNon-substrate0.7359
CYP450 1A2 substrateNon-inhibitor0.7802
CYP450 2C9 inhibitorNon-inhibitor0.9218
CYP450 2D6 inhibitorInhibitor0.5754
CYP450 2C19 inhibitorNon-inhibitor0.8195
CYP450 3A4 inhibitorNon-inhibitor0.8329
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9069
Ames testNon AMES toxic0.7985
CarcinogenicityNon-carcinogens0.886
BiodegradationNot ready biodegradable0.9161
Rat acute toxicity2.5507 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9126
hERG inhibition (predictor II)Non-inhibitor0.9191
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ah robins co
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196 °CPhysProp
logP0.49Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.58 mg/mLALOGPS
logP1.41ALOGPS
logP1.27ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)12.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.5 m3·mol-1ChemAxon
Polarizability20.43 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Phenylmethylamine
  • Benzylamine
  • Guanidine
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Imine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
Components:
NameUniProt IDDetails
Alpha-2A adrenergic receptorP08913 Details
Alpha-2B adrenergic receptorP18089 Details
Alpha-2C adrenergic receptorP18825 Details
References
  1. Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationships between platelet alpha 2-adrenoceptors and sympathetic nerve activity in clinical hypertensive states. J Hypertens. 1990 Dec;8(12):1097-104. [PubMed:1962798 ]
  2. Noshiro T, Miura Y, Kimura S, Meguro Y, Sugawara T, Ohashi H, Takahashi M, Sano N, Watanabe H, Ohzeki T, et al.: Functional relationship between platelet alpha 2-adrenoceptors and sympathetic nerve activity in man. Clin Exp Hypertens A. 1989;11 Suppl 1:287-94. [PubMed:2545383 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Bkaily G, Caille JP, Payet MD, Peyrow M, Sauve R, Renaud JF, Sperelakis N: Bethanidine increases one type of potassium current and relaxes aortic muscle. Can J Physiol Pharmacol. 1988 Jun;66(6):731-6. [PubMed:3167688 ]
  2. Bkaily G: Bethanidine, nitroprusside and atrial natriuretic factor open a cGMP-sensitive K+ channel in aortic muscle. Prog Clin Biol Res. 1990;327:507-15. [PubMed:2157221 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Hart GR, Anderson RJ: Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7. [PubMed:6114720 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Bacaner MB, Benditt DG: Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias. Am J Cardiol. 1982 Oct;50(4):728-34. [PubMed:6812406 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23